38 Result(s)
-
Article
Open AccessNiclosamide combined to Azacitidine to target TP53-mutated MDS/AML cells
-
Article
Germline CHEK2 mutations in patients with myeloid neoplasms
-
Article
Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens
-
Article
Open AccessLymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M
-
Article
Open AccessCorrection: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
-
Article
Open AccessLong-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts
-
Article
Open AccessClinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
To characterize the genomic landscape and leukemogenic pathways of older, newly diagnosed, non-intensively treated patients with AML and to study the clinical implications, comprehensive genetics analyses were...
-
Article
What role for somatic mutations in systemic inflammatory and autoimmune diseases associated with myelodysplastic neoplasms and chronic myelomonocytic leukemias?
-
Article
Clinical features and genomic landscape of myeloproliferative neoplasm (MPN) patients with autoimmune and inflammatory diseases (AID)
-
Article
What role for somatic mutations in systemic inflammatory and autoimmune diseases associated with myelodysplastic neoplasms and chronic myelomonocytic leukemias?
-
Article
Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms
-
Article
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes
-
Article
A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML
-
Article
Open AccessProspective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCO
The EUROPE phase 2 trial investigated the predictive value of biomarkers on the clinical efficacy of single agent romiplostim (ROM) treatment in patients with lower-risk myelodysplastic neoplasms (LR-MDS) and ...
-
Article
Open AccessLuspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
-
Article
Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML
The independent prognostic impact of specific dysplastic features in acute myeloid leukemia (AML) remains controversial and may vary between genomic subtypes. We apply a machine learning framework to dissect t...
-
Article
Open AccessPublisher Correction: Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study
-
Article
Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease
-
Article
Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease
-
Article
Open AccessImpact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
